{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.1","value":"3.3"},{"groupId":"OG001","spread":"30.1","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"491"},{"groupId":"OG001","value":"491"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"104.4","value":"16.8"},{"groupId":"OG001","spread":"40.9","value":"8.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"407"},{"groupId":"OG001","value":"406"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.2","value":"7.9"},{"groupId":"OG001","spread":"46.9","value":"7.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"284"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.5","value":"0.0"},{"groupId":"OG001","spread":"70.2","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.5","value":"5.0"},{"groupId":"OG001","spread":"55.1","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"270"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.0","value":"-5.4"},{"groupId":"OG001","spread":"116.1","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"491"},{"groupId":"OG001","value":"491"}],"units":"Participants"}],"description":"Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Alanine Transaminase (ALT)","type":"SECONDARY","unitOfMeasure":"Units/Liter (U/L)"}